Short Interest in ProPhase Labs, Inc. (NASDAQ:PRPH) Decreases By 25.2%

ProPhase Labs, Inc. (NASDAQ:PRPH) was the recipient of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 154,100 shares, a decrease of 25.2% from the October 15th total of 206,100 shares. Based on an average daily volume of 83,200 shares, the short-interest ratio is currently 1.9 days.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its position in shares of ProPhase Labs by 9.2% during the 3rd quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock worth $389,000 after purchasing an additional 13,590 shares in the last quarter. HighTower Advisors LLC increased its holdings in shares of ProPhase Labs by 18.3% in the 3rd quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock valued at $434,000 after purchasing an additional 27,673 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of ProPhase Labs by 1.5% in the first quarter. Vanguard Group Inc. now owns 618,763 shares of the company’s stock valued at $4,003,000 after purchasing an additional 9,416 shares during the period. Hedge funds and other institutional investors own 9.45% of the company’s stock.

ProPhase Labs Stock Performance

NASDAQ:PRPH remained flat at $0.75 during mid-day trading on Friday. 132,407 shares of the company were exchanged, compared to its average volume of 249,771. ProPhase Labs has a 1 year low of $0.66 and a 1 year high of $7.48. The firm’s fifty day moving average price is $2.16 and its 200 day moving average price is $3.24. The stock has a market cap of $17.90 million, a price-to-earnings ratio of -0.60 and a beta of -0.10. The company has a quick ratio of 1.44, a current ratio of 1.47 and a debt-to-equity ratio of 0.48.

ProPhase Labs (NASDAQ:PRPH) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.25). ProPhase Labs had a negative net margin of 217.64% and a negative return on equity of 62.92%. The business had revenue of $2.47 million during the quarter. As a group, sell-side analysts expect that ProPhase Labs will post -1.23 earnings per share for the current year.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.